Flomics specializes in advanced diagnostic technologies that utilize next-generation sequencing (NGS) and bioinformatics to analyze circulating RNA molecules in blood. Their innovative approach focuses on liquid biopsies, which allow for the non-invasive detection of cancer by identifying changes in RNA expression patterns. By examining cell-free RNA (cfRNA) present in the bloodstream, Flomics can provide a comprehensive snapshot of the biological state of various organs, enabling early detection of cancer before symptoms manifest. This capability is particularly beneficial for screening at-risk individuals, as it allows for timely intervention when treatment options are most effective.

The company employs sophisticated machine learning techniques to interpret the complex data generated from RNA sequencing. Their proprietary software platform, Stratus®, facilitates the analysis of NGS data, enhancing the reliability and reproducibility of results. Flomics' methodology goes beyond traditional mutation detection by focusing on specific gene expression patterns associated with diseases, thereby improving diagnostic accuracy. This combination of state-of-the-art sequencing technology and advanced bioinformatics positions Flomics at the forefront of liquid biopsy innovation, making significant strides in the early detection and management of cancer.

Spain

Flomics is developing novel blood-based diagnostic tools for a broad range of complex diseases. Our proprietary technology accurately identifies pattern changes in the circulating long RNA molecules of patients. With deep learning algorithms we identify RNA changes associated with disease states in a faster, cheaper and non-invasive way.

Flomics

Company Details